First Manhattan’s Immunic IMUX Stock Holding History

First Manhattan’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,000	Closed	-$2.21M	–	1615
2021 Q3	$2.21M	Buy	+25,000	New	+$2.46M	0.01%	320

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

First Manhattan's IMUX Position: Q4 2021 in Review

First Manhattan sold out of Immunic (IMUX) in Q4 2021, closing a stake of 25,000 shares — an estimated $2.21M sold.

First Manhattan first reported a position in IMUX in Q3 2021 and held it in 1 quarter. The position peaked at $2.21M in Q3 2021. 67 funds tracked by Wall St. Rank hold IMUX as of Q4 2021.

First Manhattan reported no remaining Immunic position as of Q4 2021 after selling out during the quarter.
First Manhattan sold 25,000 Immunic shares in Q4 2021, an estimated $2.21M.
First Manhattan first reported a position in Immunic in Q3 2021 and held it in 1 quarter.
First Manhattan's Immunic position peaked at $2.21M in Q3 2021.
67 funds tracked by Wall St. Rank held Immunic as of Q4 2021.

Based on First Manhattan's 13F filing for Q4 2021, filed 14 Feb 2022.